4//SEC Filing
Valantine Hannah 4
Accession 0000950170-25-084914
CIK 0001743881other
Filed
Jun 10, 8:00 PM ET
Accepted
Jun 11, 5:00 PM ET
Size
9.0 KB
Accession
0000950170-25-084914
Insider Transaction Report
Form 4
Valantine Hannah
Director
Transactions
- Exercise/Conversion
Common Stock
2025-06-10$16.75/sh+4,292$71,891→ 6,056 total - Exercise/Conversion
Stock Option (right to buy)
2025-06-10−4,292→ 34,334 totalExercise: $16.75Exp: 2033-06-21→ Common Stock (4,292 underlying) - Sale
Common Stock
2025-06-10$40.00/sh−4,292$171,680→ 1,764 total
Holdings
- 3,433(indirect: By Spouse)
Common Stock
Footnotes (2)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 5, 2024.
- [F2]The stock option vests and becomes exercisable in three annual installments starting on June 22, 2023 and ending on June 22, 2025, subject to the Reporting Person's continued service on the Issuer's Board of Directors.
Documents
Issuer
BridgeBio Pharma, Inc.
CIK 0001743881
Entity typeother
Related Parties
1- filerCIK 0001855608
Filing Metadata
- Form type
- 4
- Filed
- Jun 10, 8:00 PM ET
- Accepted
- Jun 11, 5:00 PM ET
- Size
- 9.0 KB